Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has provided an announcement.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced the convening of its 2025 first extraordinary general meeting (EGM) on December 16, 2025, in Shenzhen, China. The meeting will address significant corporate governance changes, including the abolition of the supervisory committee and amendments to the articles of association. Additionally, the election of Mr. Pu Hong as an independent non-executive director will be considered. These changes could impact the company’s governance structure and strategic direction, affecting stakeholders and potentially altering its industry positioning.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development and production of pharmaceutical products, with a market presence in Hong Kong.
Average Trading Volume: 1,265,709
Technical Sentiment Signal: Buy
Current Market Cap: HK$16.96B
For an in-depth examination of 9989 stock, go to TipRanks’ Overview page.